ReviewCancers2024
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Blood advances · 2024Trial
- Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.Chinese medical journal · 2026Article
- Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.European journal of haematology · 2026Review
- Survival outcomes and prognostic nomogram for primary pulmonary MALT lymphoma and diffuse large B-cell lymphoma: A SEER database study.Biomolecules & biomedicine · 2026Article
- Design and Synthesis of Protocatechuic Acid Derivatives for Potential Tumoricidal Effect against Hematological Malignancies.ACS omega · 2026Article
- Prediction of MYC/BCL-2 co-expression in diffuse large B-cell lymphoma using a multimodal fusion model: a retrospective study based on PET/CT habitat radiomics and deep learning.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Article
- Computational QSAR and structure-based identification of plerixafor-derived PIM-1 kinase inhibitors in diffuse large B-Cell lymphoma.Frontiers in chemistry · 2026Article
- Clinical characteristics and prognostic analysis of three hundred and nineteen cases of primary gastrointestinal diffuse large B-cell lymphoma.World journal of gastrointestinal oncology · 2025Article
- Microwave-Enhanced Synthesis of 2-Styrylquinoline-4-Carboxamides With Promising Anti-Lymphoma Activity.Archiv der Pharmazie · 2025Article
- Sequencing Anti-CD19 Therapies in Diffuse Large B-Cell Lymphoma: From Mechanistic Insights to Clinical Strategies.International journal of molecular sciences · 2025Review
- Article
- Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.Journal of clinical medicine · 2025Review
- Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.Journal of hematology & oncology · 2025Review
- Role of miRNA‑145‑5p in cancer (Review).Oncology reports · 2025Review
- What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.Cancers · 2025Review
- Prognostic genes related to mitochondrial dynamics and mitophagy in diffuse large B-cell lymphoma are identified and validated using an integrated analysis of bulk and single-cell RNA sequencing.Frontiers in immunology · 2025Article
- Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.Oncoscience · 2025Review
- Review
- Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients' chance of being cured and clinicians' therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.